Delaware Cannabis Market Analysis: A Forecast That Landed Near the Ceiling by Accident, and a Price Still Well Above It

Before Delaware's adult-use launch, Marijuana Commissioner Rob Coupe projected the state's legal cannabis market would reach $281 million in its first year — extrapolating existing medical patient spending (about $3,303/year per patient) across an estimated 85,000 future customers. Actual first-year sales came in at $53.4 million, about a fifth of that: a bad miss by any standard. Run Delaware's demographics through this framework's standard model instead — population, 18% participation, 1.0 gram/day, a $5.50/g mature-market price — and full capture at maturity comes out to roughly $293 million, within about 4% of Coupe's number. That's a genuine coincidence, not evidence he was secretly right. His method had nothing equivalent to this framework's structural analysis — no account of how licensing caps, density, or elevated pricing suppress capture below a population ceiling. He simply assumed 85,000 people would spend like Delaware's existing medical patients, with no theory for why they might not. His number landed near what a mature market could capture; it said nothing about how far short Delaware's first year would actually fall.

Market Overview

Delaware legalized medical cannabis in 2011 and adult-use possession in April 2023, when Governor John Carney allowed companion bills HB1 and HB2 to become law without his signature. What followed was a long buildout: the Office of the Marijuana Commissioner spent 2024 standing up licensing after over a thousand applicants entered two lotteries. Adult-use retail didn't begin until August 1, 2025 — delayed first by an FBI background-check issue, then by county zoning. Sussex County had used a 3-mile buffer around town boundaries to sharply limit new retail entry, though five dispensaries operated there throughout under grandfathered conversion licenses; Sussex loosened that buffer to a half-mile in November 2025, and a July 2026 veto override (SB 75) further capped what counties statewide may still restrict. Delaware's medical operators held 13 conversion licenses at launch, paying $100,000 apiece for the retail conversion (cultivation conversions ran $200,000). Rob Coupe stepped down as commissioner in January 2025, before the launch he'd planned; Joshua Sanderlin succeeded him roughly four months later.

Medical cannabis got easier to access during this same window. House Bill 285, effective mid-2024, eliminated Delaware's qualifying-condition list entirely, let patients 65+ self-certify with no practitioner involvement, and formalized 1-, 2-, or 3-year cards at $50/$75/$100, with certification tied to whichever term a patient selects rather than requiring annual renewal. Despite this loosening, 2024 medical sales fell 16% ($53.5M to $44.9M) — a decline that occurred entirely before Delaware had any in-state adult-use option. The state attributes it to patients "not renewing their patient cards and going to neighboring states," and given the timing, that's more plausible than any in-state substitution story. Enrollment will likely keep sliding now that adult-use exists — the same pattern nearly every dual-market state shows.

Fourteen dispensaries are currently listed on OMC's directory (Best Buds, Columbia Care, Field Supply, Fresh Delaware, The Farm, and Thrive Dispensary, the rebranded First State Compassion, spanning those 14 addresses) — 30 new retail licenses created by statute plus the 13 conversion licenses above, roughly 43 doors accounted for so far, with the commissioner empowered to license more. NCS's own data shows 17 retailer licenses issued, three more than are actually open — the same certificate-versus-operating-storefront gap seen elsewhere in this series.

Total Addressable Market

Delaware's population reached 1,059,952 as of Census Vintage 2025, with 19.8% under 18. Netting that via single-year-of-age data yields approximately 811,355 adults 21+. At 18% participation and 1.0 g/day, annual demand is approximately 53.3 million grams — ~$293 million at the framework's standard $5.50/g.

Delaware's sales mix isn't pure flower: NCS's combined medical-plus-adult-use breakdown puts usable flower at 53.8%, extract for inhalation (vape) at 31.9%, and solid edibles at 11.7%, with the remaining 2.6% split among liquid edibles, infused mixes, and other minor categories. Dividing revenue by a flower price produces a flower-equivalent capture estimate — an illustrative proxy, not a literal gram count.

The combined figure matters: Delaware still runs a substantial tax-exempt medical channel through the same 14 doors, so comparing adult-use revenue alone against whole-market figures elsewhere would understate it. Medical itself keeps sliding — about $2.4M/month per NCS — unsurprising once adult-use gave patients a simpler option.

Delaware's flower pricing, from a dispensary menu review conducted August 2026 (menus are dynamic; this is a point-in-time observation): mediocre eighths as low as $25 ($7.14/g), a common cluster around $35 ($10.00/g), and a decent ounce for $210 ($7.50/g). Taking $10.00/g as representative, that's roughly 80% above the $5.50/g anchor — the floor of the range still sits about 30% above it. Translating adult-use revenue specifically (not the medical-inclusive combined figure) into flower-equivalent grams at this price puts real displacement somewhat below the 18.2% dollar-capture figure.

Structural Comparison

Fourteen dispensaries against roughly 811,000 adults is approximately 1.73 per 100,000 — sparser than both Ohio and Pennsylvania.

*Combined adult-use + medical, Feb–Jul 2026 run rate (NCS), ~$80.4M annualized ÷ 14 stores; capture uses the $5.50/g anchor per this series' standard convention.

Ohio is the closest comparison: adult-use launched there a year ahead of Delaware. At Ohio's 18-month snapshot — the point its own analysis in this series is pegged to — its price already sits far closer to the mature-market anchor, and its capture already exceeds Delaware's combined figure, despite Ohio's own store growth being called too slow. Maryland shows the same dynamic at greater scale: 108 stores serving 4.7 million adults still post the highest revenue-per-store here, a sign of limited competitive pressure — plausibly the same force at work in Delaware's 14-door market.

Tax Structure

Delaware has no general state sales tax, but applies a dedicated 15% Retail Marijuana Tax to adult-use purchases — waived for medical cardholders. Seven percent of that revenue funds a Justice Reinvestment Fund. License fees are tiered and biennial: cultivation runs $2,500–$10,000 by canopy size, retail and manufacturing are $10,000, testing is $10,000; social equity and microbusiness applicants pay 40% of the open-license fee, with application fees discounted separately.

Coupe's $3,303-per-patient spending assumption is worth a second look against this series' own five-state per-patient band ($2,100–2,650/year). Delaware's actual 2024 figure — $44.9M ÷ 17,000 patients — works out to $2,641, right at that band's ceiling. Coupe's projection ran high not because he picked an unreasonable number, but because he assumed every future adult-use buyer would spend like Delaware's heaviest existing medical patients, rather than the broader, lighter-spending population an open market actually draws in.

Home Cultivation

Not permitted, for medical patients or adult-use consumers, in any form — Delaware is one of a small number of adult-use states with a complete prohibition. The real economics of growing your own suggest that costs the state less than it looks: once the price of dedicated grow space is counted honestly, home cultivation runs $815–1,937 a pound, roughly breakeven against typical retail, with real savings showing up only at heavy or medical-scale consumption. Fewer than 5% of consumers grow their own even where it's fully legal, for reasons that have little to do with price — sixteen weeks of committed space and a hundred hours of labor against fifteen minutes at a dispensary counter. Legalizing it in Delaware probably wouldn't move commercial capture much either way. No current legislative vehicle to change the prohibition appears active in the General Assembly.

The Bottom Line

Delaware's real story from here is less about where the market started than how fast it closes the gap. Combined capture already sits around 27% roughly a year into adult-use — and every lever ahead looks favorable: three more licensed retailers waiting to open, cultivation capacity still scaling past 46,000 live plants, and SB 75 clearing away the zoning fights that slowed the first wave of stores. Commissioner Sanderlin's own bet — more competition drives prices down — has real room to play out in a market this young. If Delaware's trajectory tracks Ohio's, meaningfully higher capture looks like the more likely next chapter, not a market stuck where it is now.

This analysis applies the Dan K Reports Cannabis Market Framework. For methodology, assumptions, and the complete state-by-state comparison, see the framework documentation.